Intellia Therapeutics, Inc. (NTLA): Price and Financial Metrics


Intellia Therapeutics, Inc. (NTLA)

Today's Latest Price: $23.94 USD

1.01 (-4.05%)

Updated Oct 30 4:00pm

Add NTLA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

NTLA Stock Summary

  • Of note is the ratio of Intellia Therapeutics Inc's sales and general administrative expense to its total operating expenses; just 11.89% of US stocks have a lower such ratio.
  • With a price/sales ratio of 27.72, Intellia Therapeutics Inc has a higher such ratio than 94.08% of stocks in our set.
  • As for revenue growth, note that NTLA's revenue has grown 37.71% over the past 12 months; that beats the revenue growth of 87.21% of US companies in our set.
  • Stocks that are quantitatively similar to NTLA, based on their financial statements, market capitalization, and price volatility, are KALV, VBLT, RCUS, FULC, and NXTC.
  • NTLA's SEC filings can be seen here. And to visit Intellia Therapeutics Inc's official web site, go to www.intelliatx.com.

NTLA Stock Price Chart Interactive Chart >

Price chart for NTLA

NTLA Price/Volume Stats

Current price $23.94 52-week high $27.07
Prev. close $24.95 52-week low $9.18
Day low $23.49 Volume 535,200
Day high $24.96 Avg. volume 857,422
50-day MA $22.11 Dividend yield N/A
200-day MA $18.01 Market Cap 1.41B

Intellia Therapeutics, Inc. (NTLA) Company Bio


Intellia Therapeutics a gene editing company, develops therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.


NTLA Latest News Stream


Event/Time News Detail
Loading, please wait...

NTLA Latest Social Stream


Loading social stream, please wait...

View Full NTLA Social Stream

Latest NTLA News From Around the Web

Below are the latest news stories about Intellia Therapeutics Inc that investors may wish to consider to help them evaluate NTLA as an investment opportunity.

Intellia's gene editing platforms show encouraging action in preclinical studies

Intellia Therapeutics ([[NTLA]] +0.7%) has announced new data from preclinical studies, demonstrating the persistence of in vivo CRISPR/Cas9 gene edits to either reduce a disease-causing protein or restore a functional protein, in a mouse model with accelerated liver regeneration. Data were presented at Annual Meeting of the Oligonucleotide Therapeutics Society.Lead in vivo candidate, NTLA-2001,...

Seeking Alpha | September 29, 2020

Intellia Therapeutics trades high post Goldman Sachs Buy initiation

Goldman Sachs initiated Intellia Therapeutics ([[NTLA]] +4.5%) with a Buy rating, PT $33; stock has surged 94% in the past 6 months, Wall Street Analysts (PT, $30) and Quant Rating is Bullish.Analyst Salveen Richter sees  "key value-driving events" over the next 12 months, including proof-of-concept data for lead program NTLA-2001, the...

Seeking Alpha | September 18, 2020

Intellia Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing…

GlobeNewswire | August 3, 2020

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q2 Earnings Expected to Decline

Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 30, 2020

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2020 Earnings and Company Updates

CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its second quarter 2020 financial results and operational highlights in a conference call on August 6, 2020 at 8 a.m. ET. To join the call: * U.S. callers should dial 1-877-317-6789 and international callers should dial +1-412-317-6789, approximately five minutes before the call. * All participants should ask to be connected to the Intellia Therapeutics conference call.A replay of the call will be available through the Events and Presentations page of the Investors & Media section of the company’s website at www.intelliatx.com, beginning on August ...

Yahoo | July 30, 2020

Read More 'NTLA' Stories Here

NTLA Price Returns

1-mo 19.16%
3-mo 34.42%
6-mo 72.35%
1-year 76.03%
3-year -6.01%
5-year N/A
YTD 63.19%
2019 7.47%
2018 -28.98%
2017 46.61%
2016 N/A
2015 N/A

Continue Researching NTLA

Want to see what other sources are saying about Intellia Therapeutics Inc's financials and stock price? Try the links below:

Intellia Therapeutics Inc (NTLA) Stock Price | Nasdaq
Intellia Therapeutics Inc (NTLA) Stock Quote, History and News - Yahoo Finance
Intellia Therapeutics Inc (NTLA) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7028 seconds.